Preparation method of Artemisia selengensis leaf microcapsules
Through the extraction and purification of Artemisia quinoa leaves and microencapsulation treatment, the problems of low purity and poor solubility of dibasic acid in Artemisia quinoa leaves are solved, and efficient uric acid reduction function and stability are improved.
Patent Information
- Application Number
- CN202311551874.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-17
- Publication Date
- 2025-08-12
- Estimated Expiration
- 2043-11-17
AI Technical Summary
The purity and solubility of dibasic acid in the leaves of Artemisia quinoa has low purity and poor solubility, which is easily affected by environmental factors, limiting its application in uric acid-lowering health foods.
Microcapsules were prepared by extracting and purifying the leaves of Artemisia quinoa, purifying using a macroporous adsorption resin column and combining maltodextrin and gum acacia as wall materials to improve the moldability and stability of the drug.
It improves the content and stability of dibasicone quinoic acid in Artemisia quinoa leaf microcapsules, enhances the effect of reducing uric acid, and improves the taste and drug embedding rate.
Smart Images
Figure CN117530443B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a preparation method of Artemisia selengensis leaf microcapsules and belongs to the field of health-care foods. Background Art
[0002] Artemisia selengensis, also known as Artemisia selengensis and Artemisia water wormwood, has a fragrant smell and is a plant of the genus Artemisia in the Asteraceae family, which is rich in nutrients. The tender stems of Artemisia selengensis are often eaten, and its leaves are often discarded as waste due to their bitter taste. Studies have found that Artemisia selengensis leaf extract has XOD inhibitory activity both in vivo and in vitro, and has potential preventive and therapeutic effects on hyperuricemia and gout. The di-caffeoylquinic acid (di-CQAs) rich in its extract is the main active ingredient. However, Artemisia selengensis leaves are rich in flavonoids, polyphenols, volatile oils, polysaccharides and triterpenes, and the purity of di-CQAs in the extract is low and has a strong bitter taste. In addition, phenolic acid compounds such as di-CQAs have poor solubility in water and are easily degraded and transformed by environmental factors such as oxygen and pH, which limits the development of deep-processed products of Artemisia selengensis leaves.
[0003] Microencapsulation is an effective way to encapsulate and protect active ingredients. It can convert liquid, gas or semi-solid substances into fine powders, and has many advantages such as taste masking, improving drug stability, fluidity and stability. The present invention extracts and purifies Artemisia selengensis leaves and prepares them into microcapsules, so that Artemisia selengensis leaves can be better used in uric acid-lowering health foods. Summary of the Invention
[0004] The object of the present invention is to provide an Artemisia selengensis leaf microcapsule, which uses Artemisia selengensis leaves as the main raw material, improves the formability and enhances the uric acid-lowering activity by extracting and purifying the Artemisia selengensis leaves, and improves the taste and stability of the drug by microencapsulation, thereby ultimately enabling the product to exert a better uric acid-lowering function.
[0005] To achieve the above object, the technical solution adopted by the present invention is:
[0006] A method for preparing Artemisia selengensis leaf microcapsules comprises the following steps:
[0007] (1) crushing Artemisia selengensis leaves and extracting with water, and concentrating the extract to obtain a crude Artemisia selengensis leaf extract;
[0008] (2) applying the crude extract of Artemisia selengensis leaves to a macroporous adsorption resin column, eluting with water after adsorption equilibrium, and then eluting with 10-50% ethanol, collecting the ethanol elution fraction, and concentrating to obtain a purified Artemisia selengensis leaf solution rich in dicaffeoylquinic acid;
[0009] (3) Dissolving maltodextrin and gum arabic in water to prepare a wall material solution, adding the purified Artemisia selengensis leaf solution to the wall material solution after swelling and hydration, and stirring evenly. Finally, homogenizing the mixture and spray drying it to obtain Artemisia selengensis leaf microcapsules.
[0010] Preferably, the model of the macroporous adsorption resin is HPD722.
[0011] Preferably, the concentration of the ethanol eluent is 20-40%.
[0012] Preferably, the mass ratio of maltodextrin to gum arabic is 1:1-3.
[0013] Preferably, the mass concentration of the wall material solution is 5-12%.
[0014] Preferably, the volume ratio of the Artemisia selengensis leaf purified solution to the wall material solution is 1:2-5.
[0015] Preferably, the inlet air temperature of the spray drying is 120-180° C., and the feed flow rate is 500-800 mL / h.
[0016] Preferably, the material-liquid ratio of the extraction in step (1) is 1:10-30 (g / mL), the temperature is 70-90° C., and the extraction time is 30-60 min.
[0017] According to a specific embodiment of the present invention, a better preparation method is as follows:
[0018] (1) Artemisia selengensis leaf extract
[0019] Fresh Artemisia selengensis leaves were washed, dried at 60°C, crushed, and passed through an 80-mesh sieve to obtain Artemisia selengensis leaf powder. The Artemisia selengensis leaf powder was weighed and extracted with 75°C water at a solid-liquid ratio of 1:20 (g / mL) for 40 min. The extract was filtered and the filtrate was concentrated by rotary evaporation 7 times to obtain a crude Artemisia selengensis leaf extract.
[0020] (2) Extract purification
[0021] After the HPD722 macroporous resin column is loaded, a crude extract of Artemisia selengensis leaves is loaded and sampled along the wall of the glass column while maintaining the liquid level in the column at 2 to 3 cm. The valve is controlled to allow the liquid to flow out at a rate of one drop per second. After the sample is loaded, the valve is closed and the column is allowed to stand for 2 hours. Then, impurities are eluted with distilled water until the effluent is colorless, and then eluted with 30% ethanol at the same flow rate. The ethanol eluted fraction is collected and concentrated 35 times under reduced pressure to obtain a purified Artemisia selengensis leaf solution rich in di-CQAs.
[0022] (3) Preparation of microcapsules
[0023] Maltodextrin and gum arabic were weighed in a mass ratio of 1:2, the weighed wall material was dissolved in water, and stirred evenly in a 50°C water bath until completely dissolved to obtain a wall material solution with a total concentration of 10%; the wall material solution was then placed in a 4°C refrigerator to swell overnight to complete the hydration process; the purified Artemisia selengensis leaf solution was then added to the wall material solution in a volume ratio of 1:3 and stirred evenly; finally, the mixture was high-speed homogenized at 10,000 r / min for 10 minutes and then spray-dried. The spray drying inlet air temperature was 150°C and the feed flow rate was 600 mL / h to obtain Artemisia selengensis leaf extract microcapsules rich in di-CQAs.
[0024] The beneficial effects of the present invention are:
[0025] By extracting and purifying Artemisia selengensis leaves, most impurities are removed, di-CQAs are enriched, and the exposed phenolic acids are more easily bound to polymeric colloid materials, thereby improving the drug's moldability. Furthermore, the increased di-CQAs content enhances the product's uric acid-lowering efficacy. The microcapsules prepared by this method also have the advantages of high drug encapsulation efficiency, high yield, excellent XOD enzyme inhibition, and good taste and stability. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 : Particle size detection diagram of microcapsules.
[0027] Figure 2 : Determination of release rate of microcapsules in simulated gastrointestinal digestive fluid.
[0028] Figure 3 : Static saturated adsorption capacity (left) and desorption rate (right) of six macroporous resins for di-CQAs. The results are expressed as mean ± standard deviation. Different lowercase letters in the figure indicate significant differences (P < 0.05).
[0029] Figure 4 : Static adsorption (left) and desorption (right) kinetic curves of di-CQA by three macroporous resins.
[0030] Figure 5 : di-CQAs embedding efficiency of different wall material combinations. The results are expressed as mean ± SD. Different lowercase letters in the figure indicate significant differences (P < 0.05).
[0031] Figure 6 : Microcapsule yields of different wall material combinations. The results are expressed as mean ± standard deviation. Different lowercase letters in the figure indicate significant differences (P < 0.05). DETAILED DESCRIPTION
[0032] In order to facilitate understanding of the present invention, specific embodiments of the present invention are further described below, but the present invention is not limited to the following examples.
[0033] Example 1 Preparation and evaluation of Artemisia selengensis leaf microcapsules
[0034] 1. Product Preparation
[0035] 1. Artemisia selengensis leaf extract
[0036] Fresh Artemisia selengensis leaves were washed, dried in a 60°C oven, pulverized with a high-speed grinder, and passed through an 80-mesh sieve to produce Artemisia selengensis leaf powder. The Artemisia selengensis leaf powder was weighed and extracted with 75°C distilled water at a solid-liquid ratio of 1:20 (g / mL) for 40 minutes. The extract was then filtered, and the filtrate was concentrated sevenfold by rotary evaporation to obtain a crude Artemisia selengensis leaf extract.
[0037] 2. Extract purification
[0038] After loading the column with HPD722 macroporous resin, a filtered or centrifuged crude extract of Artemisia selengensis leaves was loaded onto the glass column. The sample was then added along the column wall, maintaining the liquid level within the column at 2-3 cm. The valve was controlled to allow the liquid to flow out at a rate of approximately one drop per second. When the effluent began to leak, the loading was stopped. The valve was closed and the column was allowed to stand for approximately 2 hours. The column was first eluted with distilled water to remove impurities such as soluble sugars and proteins. After washing until the effluent was colorless, it was then eluted with 30% ethanol at the same flow rate. The ethanol-eluted fraction was collected and concentrated 35-fold under reduced pressure to obtain an Artemisia selengensis leaf extract rich in di-CQAs.
[0039] 3. Preparation of Microcapsules
[0040] Maltodextrin and gum arabic were weighed in a mass ratio of 1:2, the weighed wall material was dissolved in distilled water, and stirred evenly in a 50°C water bath until completely dissolved to obtain a wall material solution with a total concentration of 10%; the wall material solution was then placed in a 4°C refrigerator to swell overnight to complete the hydration process; the purified extract was then added to the wall material solution in a volume ratio of 1:3 and stirred evenly; finally, the mixture was high-speed homogenized at 10,000 r / min for 10 minutes and then spray-dried. The spray drying inlet air temperature was 150°C and the feed flow rate was 600 mL / h to obtain microcapsules of Artemisia selengensis leaf extract rich in di-CQAs.
[0041] 2. Product testing and performance evaluation
[0042] 1. Particle size detection
[0043] like Figure 1 As shown in the scanning electron microscopy image of the microcapsules, the average particle size of the prepared microcapsules is 6.26 μm and is evenly distributed.
[0044] 2. Evaluation of the embedding effect of di-CQAs
[0045] Ultra-high performance liquid chromatography (UPLC) was used to qualitatively and quantitatively analyze di-CQAs. Column: ACQUITY HSS T3 1.8 μm (2.1 × 100 mm column); column temperature: 25°C, flow rate: 0.2 mL / min. Mobile phase: 0.1% (volume fraction) formic acid / water (A) and acetonitrile (B). Elution: 0–1 min, 10% B; 1–4 min, 15% B; 4–5 min, 18% B; 5–18 min, 18% B; 18–19 min, 50% B; 19–21 min, 80% B; 21–23 min, 10% B; 23–25 min, 10% B. Detection wavelength: 325 nm. Injection volume: 2 μL. Prepare a 3 mg / mL sample solution of microcapsule powder, pipette 2 mL, filter through a 0.22 μm filter, and place in an injection vial.
[0046] The content of di-CQAs in the microcapsules was measured to be 13.27 mg / g, and the embedding efficiency was 95.89%.
[0047] 3. In vitro XOD inhibition rate determination
[0048] Pipette 20 μL of the sample solution to be tested into the enzyme label strip, add 100 μL of XOD enzyme solution (0.06 U / mL), and incubate at 37°C in a microplate reader for 2 minutes with interval vibration. Then, add 40 μL of xanthine solution (1 mmol / L) using a dispenser to start the reaction. Measure the absorbance of the reaction system at 295 nm every 10 seconds for a total of 2 minutes. Use phosphate buffered saline (PBS) as the blank control group. Calculate the inhibition rate of the sample on XOD enzyme activity according to the following formula:
[0049]
[0050] Where:
[0051] K0——absorbance change of blank control group;
[0052] K1 - the change in absorbance of the reaction system of the sample to be tested.
[0053] An appropriate amount of microcapsules was weighed to prepare a 25 mg / mL test sample, and the in vitro XOD inhibition rate of the microcapsules was measured to be 40.70%.
[0054] 4. Evaluation of in vitro simulated digestion effect
[0055] To prepare simulated gastric fluid: Accurately weigh 1.44g of pepsin and add 20mL of 0.01mol / L HCl solution to prepare simulated gastric digestion working solution. To prepare simulated intestinal fluid: Weigh 4g of NaCl, 0.1g of KCl, 575mg of sodium phosphate dibasic dodecahydrate, and 0.1g of potassium dihydrogen phosphate, dissolve them in distilled water, and dilute to 500mL. Adjust the pH to 7.4 with 1mol / L NaOH to prepare a phosphate buffer solution. Then, weigh 40mg of bile acid and add 20mL of phosphate buffer solution to prepare a bile salt solution. Weigh 400mg of trypsin and add 40mL of phosphate buffer solution to prepare a simulated small intestinal digestion working solution. Prepare the simulated digestion solution immediately before use and store in a refrigerator at 4°C until needed.
[0056] The prepared microcapsules were used as research objects, and the release characteristics of the core material in vivo were determined by simulating gastrointestinal digestion in vitro. The results are shown in Figure 2 .
[0057] As shown in the figure, during the simulated gastric digestion phase, the release of di-CQAs from the microcapsules initially increased and then stabilized, resulting in a low cumulative release rate. This is likely due to the release of the core material that was not encapsulated during the microcapsule preparation process. Furthermore, because the di-CQAs are covalently linked to the polymer colloidal material in the wall material, they are not easily cleaved in the acidic gastric fluid environment, thereby preventing their release. In contrast, the release rate of the unencapsulated purified sample continued to increase in acidic gastric fluid, reaching 84.04% after 120 minutes. During the intestinal digestion phase, the release rate of the microcapsules increased dramatically, reaching 73.47% after 280 minutes. This is likely due to the increased solubility of the wall material in the neutral to alkaline environment, which cleaves the covalent bonds of the di-CQAs and allows for faster drug release. As can be seen from the above, the release rate of di-CQAs from the microcapsules is low in gastric fluid but significantly increases in intestinal fluid, indicating that the wall material protects the core material, achieving a slow intestinal release effect and facilitating drug absorption and metabolism.
[0058] 5. Sensory evaluation
[0059] Sensory evaluation is conducted in accordance with national standards (GB / T15038-2006) and ISO4121. Sensory evaluators rinse their mouths with distilled water before evaluation. They hold 2-3 mL of the sample solution in their mouths for 20 seconds to allow the sample solution to fully disperse throughout the oral cavity, primarily allowing the root of the tongue to experience the bitterness. After spitting it out, they rinse their mouths with distilled water. There is a 5-10 minute rest interval between each sample. After no more bitterness remains in the mouth, the next sample is evaluated. Bitterness is divided into five levels. Evaluators determine the bitterness level of the sample based on their own taste experience and give a specific bitterness value, which is recorded in a pre-designed "bitterness rating table." The average score is used as the bitterness value, and the bitterness values of different samples are determined according to the above-mentioned bitterness determination method.
[0060] By purifying and encapsulating the Artemisia selengensis leaf extract, the bitterness of the product was reduced and the taste was improved. The results are shown in Table 1.
[0061] Table 1 Sensory evaluation results of different samples
[0062] sample Bitterness crude extract <![CDATA[4.08±0.57 a ]]> purified product <![CDATA[3.68±0.69 b ]]> microcapsules <![CDATA[1.15±0.12 c ]]>
[0063] 6. Stability evaluation
[0064] The prepared microcapsules were placed in an incubator at 40°C ± 2°C and 75% ± 5% humidity for 6 months. Samples were taken regularly to determine the di-CQAs content, and the retention rate was calculated based on the initial content. The results are shown in Table 2. Di-CQAs are chemically unstable and show a clear tendency to degrade during storage. However, encapsulation in microcapsules improved their stability.
[0065] Table 2 Stability test of microcapsules
[0066] di-CQAs retention rate January March June microcapsules 94.75％ 92.66％ 89.68％ Not encapsulated 92.84％ 81.25％ 74.39％
[0067] Example 2 Macroporous resin purification process screening test
[0068] 1. Screening of resin types
[0069] Determination of static saturated adsorption capacity and desorption rate of macroporous adsorption resin:
[0070] (1) Accurately weigh 2 g of each pretreated resin into a 50 mL conical flask, add 20 mL of the crude extract of Artemisia selengensis leaves (prepared according to the method of Example 1) to each conical flask, seal the bottle mouth with plastic wrap, and conduct constant temperature static adsorption for 12 h in a water bath shaker at 25°C and 120 r / min. Filter with suction, and store the filtrate in a 10 mL centrifuge tube (marked as "filtrate after adsorption") and store at 4°C.
[0071] (2) Rinse the surface of the adsorption-saturated macroporous adsorption resin with distilled water (shake and wash 2 to 3 times), filter and dry the surface water, then place it in a conical flask, accurately add 20 mL of 95% ethanol by volume, and desorb it at a constant temperature of 25°C and 120 r / min in a water bath shaker for 12 h. Filter and store the filtrate in a 10 mL centrifuge tube (marked as "filtrate after desorption") and store it at 4°C.
[0072] (3) Take appropriate "filtrate after adsorption" and "filtrate after desorption", determine the content of di-CQAs, and calculate the saturated adsorption capacity and desorption rate of different resins. The results are as follows: Figure 3 shown.
[0073] The saturated adsorption capacity reflects the resin's adsorption capacity, while the desorption rate reflects its desorption capacity. As shown in the figure, AB-8 resin has the highest saturated adsorption capacity for di-CQAs, but its desorption rate is relatively low. If a resin has strong adsorption capacity for the target compound but difficulty eluting it, this can reduce product yield. Therefore, a comprehensive evaluation of both the adsorption and desorption capacities of the resin is necessary. HPD100, HPD600, and HPD722 resins all have high saturated adsorption capacity and desorption rates. Therefore, these three resins were selected for the following experiments.
[0074] Static adsorption and desorption kinetics experiments of macroporous adsorption resin:
[0075] (1) Static adsorption and desorption kinetics experiments were conducted on the preliminarily screened HPD100, HPD600, and HPD722 resins. Accurately weigh 2 g of each of the three pretreated resins into a 50 mL conical flask, add 20 mL of the crude extract of Artemisia selengensis leaves (prepared according to the method of Example 1) to each conical flask, seal the bottle mouth with plastic wrap, and conduct constant temperature static adsorption for 12 h in a water bath shaker at 25°C and 120 r / min. Extract 0.5 mL of solution at 0, 0.5, 1, 1.5, 2, 3, 5, 7, 9, and 12 h, respectively, and store the solution in a 1.5 mL centrifuge tube (marked as "filtrate after adsorption") and store at 4°C.
[0076] (2) Rinse the surface of the adsorption-saturated macroporous adsorption resin with distilled water (shake and wash 2 to 3 times), filter and dry the surface water, then place it in a conical flask, accurately add 20 mL of 95% ethanol by volume, and desorb it at a constant temperature of 25°C and 120 r / min in a water bath shaker for 12 h. Draw 0.5 mL of solution at 0, 0.5, 1, 1.5, 2, 3, 5, 7, 9, and 12 h, respectively, and store the solution in a 1.5 mL centrifuge tube (marked as "filtrate after desorption") and store it at 4°C.
[0077] (3) Take the "filtrate after adsorption" and "filtrate after desorption" of each time period, determine the di-CQAs content, calculate its saturated adsorption capacity and desorption rate based on the di-CQAs content, and draw the static adsorption kinetic curve and static desorption kinetic curve with the detection time as the horizontal axis. The results are as follows: Figure 4 shown.
[0078] From the adsorption kinetics curve ( Figure 2 As can be seen from the figure (left), the adsorption of di-CQAs by the three resins reached saturation within 2 hours, with a fast adsorption rate, belonging to the rapid equilibrium type. In the first 0.5 hours, the adsorption of di-CQAs by the three resins increased rapidly. After 2 hours, the adsorption reached equilibrium. At this time, the saturated adsorption capacity of the three resins was around 30 mg / g, with no significant difference. From the desorption kinetic curve ( Figure 2 (Right) It can be seen that in the 0-0.5 h stage, the three resins desorbed rapidly, and the desorption gradually reached equilibrium after 1 h. Since the desorption rate of HPD722 resin was greater than that of the other two resins, HPD722 resin was selected as the best resin for purifying di-CQAs.
[0079] 2. Screening of elution solvents
[0080] After loading the column with HPD722 resin, a filtered or centrifuged crude extract of Artemisia selengensis leaves is loaded onto the glass column. The sample is then added along the wall of the column, maintaining the liquid level within the column at 2-3 cm. The valve is controlled to allow the liquid to flow out at a rate of approximately one drop per second. When the effluent begins to leak, the sample loading is stopped. The valve is closed and the column is allowed to stand for approximately 2 hours. First, elution with distilled water is performed to remove impurities such as soluble sugars and proteins. After washing until the effluent is colorless, elution is then performed sequentially with 10%, 30%, and 50% ethanol at the same flow rate. The eluates from the different ethanol concentrations are collected, and the crude Artemisia selengensis leaf extract, the 10%, 30%, and 50% ethanol elution fractions are concentrated under reduced pressure and freeze-dried to obtain a freeze-dried powder.
[0081] The freeze-dried powder was used to prepare the sample solution to be tested. The purity, yield and in vitro XOD inhibition rate of di-CQAs before and after purification were determined. The results are shown in Table 3.
[0082] The purity, yield and yield of the sample were calculated according to the following formula:
[0083]
[0084]
[0085] Table 3 Purity, yield and IC of di-CQAs before and after purification 50 value
[0086]
[0087]
[0088] Note: Different lowercase letters in the same column indicate significant differences (P < 0.05).
[0089] The results showed that the di-CQAs in the 30% ethanol elution fraction were of higher purity and exhibited stronger XOD inhibitory activity. Compared to the crude extract, the di-CQAs in the 30% ethanol elution fraction were 4.35 times purer. Therefore, the 30% ethanol elution fraction was selected as the eluent for macroporous resin purification.
[0090] Example 3 Microcapsule preparation process screening test
[0091] 1. Screening of wall material types
[0092] The choice of microcapsule wall material is closely related to the type of core material. Di-CQAs belong to the phenolic acid class of compounds and are easily covalently linked to polymeric colloidal materials through ester bonds to form stable bound phenolic acids. The different viscosities and dispersibilities of various wall materials will directly affect the encapsulation efficiency and yield of microcapsules. The applicant found through preliminary experiments that a single wall material is difficult to meet the requirements of microencapsulation processes and products. Therefore, this experiment selected several commonly used microcapsule wall material combinations for testing. The results showed that all four wall material combinations had good powdering properties. Except for the product made by the combination of maltodextrin and gum arabic, which was light yellow, the products of the other three combinations were milky white. The product of the combination of maltodextrin and gum arabic (MD+GA) had less wall adhesion and less raw material loss during the spray drying process. The combination of gum arabic and soy protein isolate (GA+SPI) had severe wall adhesion and greater product loss. The mixed liquid of the other two combinations easily stratified during spray drying and was unstable. In order to more objectively evaluate the performance of the wall material, the embedding efficiency and microcapsule yield were measured and calculated. The results showed that the combination of maltodextrin and gum arabic (MD+GA) and gum arabic and soy protein isolate (GA+SPI) had a higher embedding efficiency for di-CQAs ( Figure 5 The yield of maltodextrin and gum arabic (MD+GA) and maltodextrin + whey protein isolate (MD+WPI) was higher, and the yield of gum arabic + whey protein isolate (GA+WPI) was the second highest. Figure 6 ). After comprehensive analysis, maltodextrin and gum arabic were selected as the best wall materials.
[0093]
[0094]
[0095] 2. Optimization of process conditions
[0096] According to the preliminary test results, the wall material mass ratio, wall material mass fraction and core-to-wall ratio were selected as the three investigation factors, and each factor was taken at three levels. 9 (3 3 ) orthogonal table was used to conduct orthogonal test and the optimal process conditions for preparing microcapsules by spray drying were determined with the di-CQAs embedding efficiency as the index.
[0097] Table 4 Orthogonal test factor level table
[0098]
[0099] Table 5 Microcapsule orthogonal test design and results
[0100] Test No. A wall material quality ratio B wall material mass fraction C core-to-wall ratio Embedding rate (%) 1 1 1 1 88.15±0.05 2 1 2 2 90.49±0.08 3 1 3 3 92.16±0.44 4 2 1 2 92.09±0.11 5 2 2 3 93.24±0.09 6 2 3 1 91.81±0.01 7 3 1 3 94.49±0.12 8 3 2 1 93.16±0.05 9 3 3 2 95.78±0.09 <![CDATA[K1]]> 90.267 91.577 91.040 <![CDATA[K2]]> 92.380 92.297 92.787 <![CDATA[K3]]> 94.477 93.250 93.297 R 4.210 1.673 2.257
[0101] According to Table 5, the range R A >R C >R B The influence of the three factors on the encapsulation effect of di-CQAs is: A>C>B, that is, the ratio of composite wall materials has the greatest influence on the encapsulation rate. The optimal process parameter combination for microcapsule preparation is A3B3C3, that is, the ratio of maltodextrin to gum arabic is 1:2, the mass fraction of wall material is 10%, and the ratio of core material to wall material is 1:3.
Claims
1. A method for preparing Artemisia selengensis leaf microcapsules with uric acid-lowering effect, characterized in that: The following steps are involved: (1) crushing Artemisia selengensis leaves and extracting with water, and concentrating the extract to obtain a crude Artemisia selengensis leaf extract; (2) The crude extract of Artemisia selengensis leaves was applied to an HPD722 macroporous adsorption resin column. After adsorption equilibrium, the extract was first eluted with water and then with 30% ethanol. The ethanol elution fraction was collected and concentrated to obtain a purified Artemisia selengensis leaf extract rich in dicaffeoylquinic acid. (3) Dissolving maltodextrin and gum arabic in water to prepare a wall material solution, adding the purified Artemisia selengensis leaf solution to the wall material solution after swelling and hydration, and stirring evenly. Finally, homogenizing the mixture and spray drying it to obtain Artemisia selengensis leaf microcapsules, wherein the mass ratio of maltodextrin to gum arabic is 1:2, the concentration of the wall material solution is 10%, and the volume ratio of the purified Artemisia selengensis leaf solution to the wall material solution is 1:
3.
2. The method for preparing Artemisia selengensis leaf microcapsules according to claim 1, wherein: The inlet air temperature of the spray drying is 120-180° C., and the feed flow rate is 500-800 mL / h.
3. The method for preparing Artemisia selengensis leaf microcapsules according to claim 1, wherein: The material-liquid ratio of the extraction in step (1) is 1:10-30 (g / mL), the temperature is 70-90°C, and the extraction time is 30-60 minutes.